Novel mutations in MYBPC1 are associated with myogenic tremor and mild myopathy

Objective To define a distinct, dominantly inherited, mild skeletal myopathy associated with prominent and consistent tremor in two unrelated, three‐generation families. Methods Clinical evaluations as well as exome and panel sequencing analyses were performed in affected and nonaffected members of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of neurology 2019-07, Vol.86 (1), p.129-142
Hauptverfasser: Stavusis, Janis, Lace, Baiba, Schäfer, Jochen, Geist, Janelle, Inashkina, Inna, Kidere, Dita, Pajusalu, Sander, Wright, Nathan T., Saak, Annika, Weinhold, Manja, Haubenberger, Dietrich, Jackson, Sandra, Kontrogianni‐Konstantopoulos, Aikaterini, Bönnemann, Carsten G.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective To define a distinct, dominantly inherited, mild skeletal myopathy associated with prominent and consistent tremor in two unrelated, three‐generation families. Methods Clinical evaluations as well as exome and panel sequencing analyses were performed in affected and nonaffected members of two families to identify genetic variants segregating with the phenotype. Histological assessment of a muscle biopsy specimen was performed in 1 patient, and quantitative tremor analysis was carried out in 2 patients. Molecular modeling studies and biochemical assays were performed for both mutations. Results Two novel missense mutations in MYBPC1 (p.E248K in family 1 and p.Y247H in family 2) were identified and shown to segregate perfectly with the myopathy/tremor phenotype in the respective families. MYBPC1 encodes slow myosin binding protein‐C (sMyBP‐C), a modular sarcomeric protein playing structural and regulatory roles through its dynamic interaction with actin and myosin filaments. The Y247H and E248K mutations are located in the NH2‐terminal M‐motif of sMyBP‐C. Both mutations result in markedly increased binding of the NH2 terminus to myosin, possibly interfering with normal cross‐bridge cycling as the first muscle‐based step in tremor genesis. The clinical tremor features observed in all mutation carriers, together with the tremor physiology studies performed in family 2, suggest amplification by an additional central loop modulating the clinical tremor phenomenology. Interpretation Here, we link two novel missense mutations in MYBPC1 with a dominant, mild skeletal myopathy invariably associated with a distinctive tremor. The molecular, genetic, and clinical studies are consistent with a unique sarcomeric origin of the tremor, which we classify as “myogenic tremor.” ANN NEUROL 2019
ISSN:0364-5134
1531-8249
DOI:10.1002/ana.25494